InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.39
(
0.00%
)
US TECH 100
18,066.40
(
0.28%
)
Dow Jones
39,357.01
(
-0.36%
)
Brent Oil
81.27
(
-0.42%
)
Bitcoin
59,177.00
(
-0.30%
)
Post# of 252864
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120262
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 120024

Sunday, 05/15/2011 2:23:05 PM

Sunday, May 15, 2011 2:23:05 PM

Post# of 252864
The BioCentury FoB article gets to the crux of the issue: Should a company develop an FoB, where the clinical program can be somewhat abbreviated and FDA approval in one indication may extend to related indications (#msg-58469454)… or should a company develop a regular biologic (via the BLA pathway), and thereby avoid disclosing IP to competitors?

If an applicant expects to achieve interchangeability, the FoB pathway is clearly preferable; however, if interchangeability is out of the question, the answer to the above question is not easily determined.

“The notion that there’s a Chinese Wall between sell-side analysts
and investment bankers may be the second-biggest piece of BS
ever promulgated in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up